Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 391Neoplasms 383Lung Neoplasms 265Multiple Myeloma 249Colorectal Neoplasms 235Neoplasm Metastasis 216Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 165Pancreatic Neoplasms 156Carcinoma, Renal Cell 142Squamous Cell Carcinoma of Head and Neck 141Lymphoma 137Brain Neoplasms 133Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 125Lymphoma, Non-Hodgkin 124Carcinoma, Hepatocellular 119Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 99Lymphoma, Follicular 96Sarcoma 95

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Malignant Ascites × 1 year × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡